Humanin vs MOTS-c
Both Humanin and MOTS-c are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Humanin | MOTS-c |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — mitochondrial-derived peptide research compound | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | Research range: 0.5–1 mg subcutaneous (rare clinical use) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 5 | 22 |
| Categories | mitochondrial, longevity, neuroprotection | metabolic, longevity |
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.